Medtrade exhibitor Resmed has launched NightOwl™, a new home sleep apnea test.

New meta-analysis demonstrates that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA).

Resmed recently introduced a comprehensive brand evolution designed to unify its brand portfolio.

If at least some patients are covered by Medicare, suppliers need to be aware of the federal laws.

ResMed revenue for the quarter ended Dec. 31, 2024 increased 10% to $1.3 billion; up 10%.

The purpose is to ensure that the CPAP device is medically necessary by preventing the CPAP supplier’s financial interest from creeping into the diagnosis and treatment.